Loading...
Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report
SMARCA4‐deficient thoracic sarcoma (SMARCA4‐DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4‐DTS have not yet been developed. Most recently, anti‐programmed cell death 1 receptor (PD‐1) blockade h...
Na minha lista:
| Udgivet i: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons Australia, Ltd
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6885443/ https://ncbi.nlm.nih.gov/pubmed/31617320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13215 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|